## Maximizing immunoassay performance in modern biopharma

[Read more](/content/spinblog/improving-quality-and-speed-in-immunoassay-development/index.html)

## Advantages of small-volume analytical technologies in gene therapy

[Read more](/content/spinblog/advantages-of-small-volume-analytical-technologies-in-gene-therapy/index.html)

## Advantages of Automated Immunoassays

[Read more](/content/spinblog/advantages-of-automated-immunoassays/index.html)

## Automated detection of dsRNA contaminants in mRNA samples

[Read more](/content/spinblog/automated-detection-of-dsrna-contaminants-in-mrna-samples/index.html)

## Gyrolab automated platform – faster delivery of immunoassay data and more information per data point

[Read more](/content/spinblog/gyrolab-automated-platform-faster-delivery-of-immunoassay-data-and-more-information-per-data-point/index.html)

## Choosing the Right Automated Immunoassay Platform for Your Analytical Needs

[Read more](/content/spinblog/choosing-the-right-automated-immunoassay-platform-for-your-bioprocess-needs/index.html)

## Automated hybridization assays to measure ASO drug levels in biological samples

[Read more](/content/spinblog/automated-hybridization-assays-to-measure-aso-drug-levels-in-biological-samples/index.html)

## Generic assays for ADA assessment in rodents

[Read more](/content/spinblog/immunoassays/generic-assays-for-ada-assessment-in-rodents/index.html)

## Host Cell Protein (HCP) Impurities in Biotherapeutic Drug Development and Manufacturing

[Read more](/content/spinblog/host-cell-protein-hcp-impurities-in-biotherapeutic-drug-development-and-manufacturing/index.html)

## New Gyros Protein Technologies Kit Boxes Launch

[Read more](/content/spinblog/new-gyros-protein-technologies-kit-boxes-launch/index.html)

## Pre-existing anti-AAV immunity: a hidden barrier to gene therapy

[Read more](/content/spinblog/pre-existing-anti-aav-immunity-a-hidden-barrier-to-gene-therapy/index.html)

## Enhancing AAV gene therapy: Insights from Bayer’s immunogenicity testing study

[Read more](/content/spinblog/enhancing-aav-gene-therapy-insights-from-bayers-immunogenicity-testing-study/index.html)

## Overcoming Challenges in Electrochemiluminescence Assays (ECLA) During Pre-Clinical PK Studies with Microfluidic Technology

[Read more](/content/spinblog/overcoming-challenges-in-electrochemiluminescence-assays-ecla-during-pre-clinical-pk-studies-with-microfluidic-technology/index.html)

## How to Address ELISA Challenges in Preclinical PK Studies with Advanced Microfluidic Technology

[Read more](/content/spinblog/how-to-address-elisa-challenges-in-preclinical-pk-studies-with-advanced-microfluidic-technology/index.html)

## Advancing PK Studies: The Role of Microsampling in Monoclonal Antibody Therapeutics

[Read more](/content/spinblog/advancing-pk-studies-the-role-of-microsampling-in-monoclonal-antibody-therapeutics/index.html)

## Anti-interferon autoantibodies play a major role in the age-related severity of COVID-19

[Read more](/content/spinblog/anti-interferon-autoantibodies-play-a-major-role-in-the-age-related-severity-of-covid-19/index.html)

## Matching microsampling with miniaturized bioanalysis is revolutionizing pharma biotherapeutic development

[Read more](/content/spinblog/matching-miniaturized-bioanalysis-with-microsampling-is-revolutionizing-pharma-biotherapeutic-development/index.html)

## Accurate ligand affinity determination: in-solution Adnectin KD measurement

[Read more](/content/spinblog/accurate-ligand-affinity-determination-is-crucial-when-targeting-protein-protein-interactions-2/index.html)

## Accurate ligand affinity determination: high-affinity ligands for use in cancer immunotherapy

[Read more](/content/spinblog/accurate-ligand-affinity-determination-is-crucial-when-targeting-protein-protein-interactions/index.html)

## Boost COVID-19 vaccine R&D with rapid serology tests and minimal sample and reagent consumption (Part III)

[Read more](/content/spinblog/boost-covid-19-vaccine-rd-with-rapid-serology-tests-and-minimal-sample-and-reagent-consumption-part-iii/index.html)

## Immunoassays to measure SARS-CoV-2 antibodies in serum (Part II)

[Read more](/content/spinblog/immunoassays-to-measure-sars-cov-2-antibodies-in-serum-part-ii/index.html)

## Serology tests in COVID-19 research and vaccine development (Part I)

[Read more](/content/spinblog/serology-tests-in-covid-19-research-and-vaccine-development-part-i/index.html)

## Capsid titer quantification for AAV-based therapeutics

[Read more](/content/spinblog/aav-capsid-titer-quantification-gyrolab/index.html)

## A new spin on ultra-high biomolecular affinity determination

[Read more](/content/spinblog/a-new-spin-on-ultra-high-biomolecular-affinity-determination/index.html)

## Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part I

[Read more](/content/spinblog/boosting-vaccine-development-and-production-in-a-post-pandemic-era-with-fast-high-performance-immunoassays-part-1/index.html)

## Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part II

[Read more](/content/spinblog/boosting-vaccine-development-and-production-in-a-post-pandemic-era-with-fast-high-performance-immunoassays-part-2/index.html)

## How to think about HCP impurity testing

[Read more](/content/spinblog/how-to-think-about-hcp-impurity-testing/index.html)

## Enhancing the productivity of immunoassays: a 2-plex Gyrolab assay for both preclinical and clinical studies

[Read more](/content/spinblog/enhancing-the-productivity-of-immunoassays-a-2-plex-gyrolab-assay-for-both-preclinical-and-clinical-studies/index.html)

## How to be confident in immunoassay determination of free versus bound target or drug

[Read more](/content/spinblog/quantitation-of-free-versus-bound-biotherapeutic/index.html)

## Improving quality and speed in immunoassay development, validation, and routine use

[Read more](/content/spinblog/immunoassay-development-validation/index.html)

## Weighing up the advantages and disadvantages of multiplex assays

[Read more](/content/spinblog/multiplex-assays-advantages-disadvantages/index.html)

## Solutions to immunoassay interference, cross reactivity and other challenges

[Read more](/content/spinblog/immunoassay-interference-crossreactivity-challenges/index.html)

## Putting a new spin on immunoassays for cell and gene therapy – Part 2

[Read more](/content/spinblog/putting-a-new-spin-on-immunoassays-for-cell-and-gene-therapy-part-2/index.html)

## Putting a new spin on immunoassays for gene therapy – Part 1

[Read more](/content/spinblog/putting-a-new-spin-on-immunoassays-for-gene-therapy-part-1/index.html)

## Next generation antibody therapeutics move into prokaryotes

[Read more](/content/spinblog/next-generation-antibody-therapeutics-move-into-prokaryotes/index.html)

## Ligand binding assays for regulated bioanalysis

[Read more](/content/spinblog/ligand-binding-assays-for-regulated-bioanalysis/index.html)

## How to get it right the first time

[Read more](/content/spinblog/how-to-get-it-right-the-first-time/index.html)

## ADME of therapeutic proteins

[Read more](/content/spinblog/adme-of-therapeutic-proteins/index.html)